Mundipharma competitive analysis

Explore patent oppositions filed by Mundipharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 17, 2026
Patent NumberTitleApplicantOpposition Date
Treatment Of Hematologic Malignancies Associated With Circulating Tumor Cells Using Chimeric Anti-Cd20 AntibodyBIOGENMay 11, 2017
Method For Treating Joint DamageBIOGEN IDECApr 10, 2017
Method For Treating Joint DamageBIOGEN IDECApr 7, 2017

Explore Mundipharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 17, 2026
Patent NumberPublication DateTitleTotal Oppositions
May 10, 2017Pharmaceutical Preparation Containing Oxycodone And Naloxone11
May 10, 2017Pharmaceutical Preparation Containing Oxycodone And Naloxone11
Mar 1, 2017Pharmaceutical Preparation Containing Oxycodone And Naloxone10
May 1, 2013Sustained Analgesia Achieved With Transdermal Delivery Of Buprenorphine3

Latest PTAB cases involving Mundipharma

Discover the latest PTAB cases involving Mundipharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Mundipharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 17, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MUNDIPHARMA235 - -
BIOGEN68 - 12
BIOGEN IDEC - 17 - -
GALLAFENT, ALISON2 - - -